about
sameAs
Use of a commercially available line probe assay for genotyping of hepatitis C virus 5a strains.Investigating the Origin and Spread of Hepatitis C Virus Genotype 5aEvaluation of Versant Hepatitis C Virus Genotype Assay (LiPA) 2.0Evidence for a complex mosaic genome pattern in a full-length hepatitis C virus sequenceProgressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's diseaseDetection of perinatal cytomegalovirus infection and sensorineural hearing loss in belgian infants by measurement of automated auditory brainstem responseExhaled breath condensate sampling is not a new method for detection of respiratory virusesAntiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.A near-full length genotypic assay for HCV1b.A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors.Evaluation of the efficacy of disinfectants against Puumala hantavirus by real-time RT-PCR.Quantitation of replication of the HCV genome in human livers with end-stage cirrhosis by strand-specific real-time RT-PCR assays: methods and clinical relevance.HCV genotype distribution in Flanders and Brussels (Belgium): unravelling the spread of an uncommon HCV genotype 5a cluster.Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study.HCV genotype 5: epidemiology and spread of an uncommon genotype.Molecular evolutionary analysis and mutational pattern of full-length genomes of hepatitis B virus isolated from Belgian patients with different clinical manifestations.Molecular characterization of hepatitis B virus strains circulating in Belgian patients co-infected with HIV and HBV: overt and occult infection.Phylogenetic analysis of hepatitis B virus full-length genomes reveals evidence for a large nosocomial outbreak in Belgium.Frequency of the CCR5-Delta32 mutant allele is not increased in Belgian hepatitis C virus-infected patients.JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
P50
Q27472773-98028C4F-2867-4700-A4D5-FDBFA4F431EAQ27473217-8F6B5159-8982-461D-AA1D-3A0C16440922Q27486402-EACE2EB9-E9C2-4B9A-BF4E-6E1ECD9E1F3FQ27487545-9613CCF3-B0D7-40FB-A059-E3DEBD9C5CD1Q28255557-2CD30874-BE9E-4049-96FD-B9B2DA674976Q30489931-34FF8072-1127-4DCD-B8E3-10C437AF9240Q34687022-C40F94EB-F294-46A2-AF9C-A8B44D0EA42BQ37274730-E6D11BE4-53EC-434F-B1B3-C8BA7D8DE46AQ38958702-D0332EAB-AA91-48A3-A704-146F7A59D1B6Q39131364-7AF03715-EDE7-4DA2-9F53-A36F04879915Q40461481-CBEE2DE5-E0EC-49FD-8F8D-6EC444A7D5BAQ42989523-94F18FF0-05CF-4951-8118-1B494DAA86D2Q42999804-F070CD14-1292-43F9-A843-E61EDA7621E8Q43033457-CEF5F356-BCA8-4E3C-92AA-280D9AA71EDCQ43048300-4ABF5D9F-8B52-4A98-865C-3C5348AB37A0Q43188987-33D818D8-0053-400B-9F73-98036C3AB378Q43498043-94B248E6-689E-4C70-97CB-76D68C34959BQ45382725-6D2834C3-BD5D-4344-9501-E1070BCF942BQ45488406-0F6593A3-D3FB-44D8-AFAF-A494742D6474Q46626939-A2A5DDCC-6F9B-419B-BBE7-294608847B7E
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jannick Verbeeck
@ast
Jannick Verbeeck
@en
Jannick Verbeeck
@es
Jannick Verbeeck
@nl
Jannick Verbeeck
@sl
type
label
Jannick Verbeeck
@ast
Jannick Verbeeck
@en
Jannick Verbeeck
@es
Jannick Verbeeck
@nl
Jannick Verbeeck
@sl
prefLabel
Jannick Verbeeck
@ast
Jannick Verbeeck
@en
Jannick Verbeeck
@es
Jannick Verbeeck
@nl
Jannick Verbeeck
@sl
P1053
P-6027-2017
P106
P21
P31
P3829
P496
0000-0001-7226-1398